<?xml version='1.0' encoding='utf-8'?>
<document id="20406837"><sentence text="Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors."><entity charOffset="48-58" id="DDI-PubMed.20406837.s1.e0" text="paclitaxel" /><entity charOffset="63-74" id="DDI-PubMed.20406837.s1.e1" text="trabectedin" /><pair ddi="false" e1="DDI-PubMed.20406837.s1.e0" e2="DDI-PubMed.20406837.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20406837.s1.e0" e2="DDI-PubMed.20406837.s1.e1" /></sentence><sentence text="This phase I study evaluated the feasibility, safety, pharmacokinetics (PK), and preliminary evidence of anticancer activity of the sequential administration of paclitaxel and trabectedin on an every-2-week schedule in patients with refractory solid malignancies"><entity charOffset="161-171" id="DDI-PubMed.20406837.s2.e0" text="paclitaxel" /><entity charOffset="176-187" id="DDI-PubMed.20406837.s2.e1" text="trabectedin" /><pair ddi="false" e1="DDI-PubMed.20406837.s2.e0" e2="DDI-PubMed.20406837.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20406837.s2.e0" e2="DDI-PubMed.20406837.s2.e1" /></sentence><sentence text=" The study also sought to determine the maximum tolerated dose (MTD) level on this schedule, as well as to recommend doses for disease-directed studies" /><sentence text="" /><sentence text="Twenty-seven patients were treated with paclitaxel (80-120 mg/m(2); 1-hour i"><entity charOffset="40-50" id="DDI-PubMed.20406837.s5.e0" text="paclitaxel" /></sentence><sentence text="v" /><sentence text=" infusion, day 1) and trabectedin (0"><entity charOffset="22-33" id="DDI-PubMed.20406837.s7.e0" text="trabectedin" /></sentence><sentence text="525-0" /><sentence text="775 mg/m(2); 3-hour i" /><sentence text="v" /><sentence text=" infusion, day 2) with doses increased in successive cohorts" /><sentence text=" Blood sampling for PK and drug-drug interaction studies was done" /><sentence text="" /><sentence text="Neutropenia, which resulted in treatment delay exceeding 1 week, was the principal dose-limiting toxicity for this paclitaxel-trabectedin regimen and precluded dose escalation above 120 mg/m(2) paclitaxel and 0"><entity charOffset="115-125" id="DDI-PubMed.20406837.s14.e0" text="paclitaxel" /><entity charOffset="126-137" id="DDI-PubMed.20406837.s14.e1" text="trabectedin" /><entity charOffset="194-204" id="DDI-PubMed.20406837.s14.e2" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.20406837.s14.e0" e2="DDI-PubMed.20406837.s14.e0" /><pair ddi="false" e1="DDI-PubMed.20406837.s14.e0" e2="DDI-PubMed.20406837.s14.e1" /><pair ddi="false" e1="DDI-PubMed.20406837.s14.e0" e2="DDI-PubMed.20406837.s14.e2" /><pair ddi="false" e1="DDI-PubMed.20406837.s14.e1" e2="DDI-PubMed.20406837.s14.e1" /><pair ddi="false" e1="DDI-PubMed.20406837.s14.e1" e2="DDI-PubMed.20406837.s14.e2" /></sentence><sentence text="650 mg/m(2) trabectedin" /><sentence text=" At the MTD (120 mg/m(2) paclitaxel and 0"><entity charOffset="8-11" id="DDI-PubMed.20406837.s16.e0" text="MTD" /><entity charOffset="25-35" id="DDI-PubMed.20406837.s16.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.20406837.s16.e0" e2="DDI-PubMed.20406837.s16.e0" /><pair ddi="false" e1="DDI-PubMed.20406837.s16.e0" e2="DDI-PubMed.20406837.s16.e1" /></sentence><sentence text="650 mg/m(2) trabectedin), the safety profile was favorable in patients receiving cumulative treatment" /><sentence text=" Relevant drug-drug PK interactions between paclitaxel and trabectedin were not identified"><entity charOffset="44-54" id="DDI-PubMed.20406837.s18.e0" text="paclitaxel" /><entity charOffset="59-70" id="DDI-PubMed.20406837.s18.e1" text="trabectedin" /><pair ddi="false" e1="DDI-PubMed.20406837.s18.e0" e2="DDI-PubMed.20406837.s18.e0" /><pair ddi="false" e1="DDI-PubMed.20406837.s18.e0" e2="DDI-PubMed.20406837.s18.e1" /></sentence><sentence text=" A patient with soft tissue sarcoma had a complete response and several patients with various refractory solid malignancies showed protracted stable disease as their best response" /><sentence text="" /><sentence text="The MTD level of sequential paclitaxel 1-hour infusion (day 1) and trabectedin 3-hour infusion (day 2) administered every 2 weeks is 120 and 0"><entity charOffset="28-38" id="DDI-PubMed.20406837.s21.e0" text="paclitaxel" /><entity charOffset="4-13" id="DDI-PubMed.20406837.s21.e1" text="MTD" /><pair ddi="false" e1="DDI-PubMed.20406837.s21.e1" e2="DDI-PubMed.20406837.s21.e1" /><pair ddi="false" e1="DDI-PubMed.20406837.s21.e1" e2="DDI-PubMed.20406837.s21.e0" /></sentence><sentence text="650 mg/m(2), respectively" /><sentence text=" The manageable toxicities at the MTD, preliminary evidence of antitumor activity, and lack of notable PK drug-drug interactions warrant further disease-directed studies of this regimen in relevant tumor types and settings"><entity charOffset="34-36" id="DDI-PubMed.20406837.s23.e0" text="MTD" /></sentence><sentence text="" /></document>